3648_EchoIQ-ES_Logo_FA_RGB_REV

AI-Powered EchoSolv Clinical Cohort Study Identifies 72% More Patients with Severe Aortic Stenosis and Reduces Gender Bias

Augmented detection of severe aortic stenosis in Women and Men with artificial intelligence: An adjudication blinded clinical cohort study.

Linkedin Twitter

Prof Geoffrey A. Strange, PhD; Prof Michael P. Feneley, MD; Prof David Prior, MBBS PhD; Prof David Muller, MD; Dr Prasanna Venkataraman, MD; Dr Yiling Situ, MBBS; Prof Simon Stewart, DMSc; Prof David Playford, MBBS PhD

Corresponding Author

Professor Geoff Strange
The University of Notre Dame Australia
32 Mouat St, Fremantle WA 6160
E: [email protected]
T: +61 422 308 585

Key Question

When compared to routine clinical detection and management, can machine learning/artificial intelligence (AI) techniques augment the detection of guideline-defined severe AS with potential to redirect more women and men to appropriate management?

Key Findings

An AI automated alert system (AI-AAS) specifically designed to detect severe AS
from routinely reported echocardiographic measurements, has the potential to
redirect 1.6 to 2.1-fold more men and women with guideline-defined severe AS
towards more definitive care from the heart care team.

Take-home Message

A significant proportion of individuals (particularly women) being managed within a high-quality tertiary referral setting are potentially being overlooked for management of guideline defined, severe AS. If routinely applied, an AI-AAS has strong potential to appropriately redirect these individuals towards (consideration of) this life-saving treatment.

This study will be presented as late-breaking science at the European Society of Cardiology 2023 congress.

Download the press kit

Book an interview with the team behind EchoSolv

white_logo

Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.

Echo IQ Limited 

  • Address: Suite 404, 309 George Street, Sydney NSW 2000, Australia
  • Phone: +61 (0) 2 9159 3719
  • ABN 48 142 901 353
Linkedin Twitter
white_logo
Echo IQ has developed an AI diagnostic tool that will revolutionise the diagnosis of structural heart disease. Specifically, it is designed to reduce the incidence of undetected and misdiagnosed cardiac issues.

Echo IQ Limited 

  • Address: Suite 404, 309 George Street, Sydney NSW 2000, Australia
  • Phone: +61 (2) 9159 3719
  • ABN 48 142 901 353
Linkedin Twitter
#aiwithheart

EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool. Full
phenotyping capabilities will be available pending FDA approval.

All rights reserved. Copyright © 2023 Echo IQ.
Designed and Developed by Brand for Brands.